554 related articles for article (PubMed ID: 10717628)
1. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
2. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
Ansari MS; Gupta NP
Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
[TBL] [Abstract][Full Text] [Related]
3. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
[TBL] [Abstract][Full Text] [Related]
4. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
Dimopoulos MA; Panopoulos C; Bamia C; Deliveliotis C; Alivizatos G; Pantazopoulos D; Constantinidis C; Kostakopoulos A; Kastriotis I; Zervas A; Aravantinos G; Dimopoulos C
Urology; 1997 Nov; 50(5):754-8. PubMed ID: 9372887
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.
Pienta KJ; Redman BG; Bandekar R; Strawderman M; Cease K; Esper PS; Naik H; Smith DC
Urology; 1997 Sep; 50(3):401-6; discussion 406-7. PubMed ID: 9301705
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Pienta KJ; Smith DC
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
[TBL] [Abstract][Full Text] [Related]
9. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
[TBL] [Abstract][Full Text] [Related]
11. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer.
Nishimura K; Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Imazu T; Takaha N; Sugao H; Miki T; Okuyama A
Oncology; 2001; 60(1):49-54. PubMed ID: 11150908
[TBL] [Abstract][Full Text] [Related]
12. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
[TBL] [Abstract][Full Text] [Related]
16. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
17. [Hormonal chemotherapy for hormone-refractory prostate cancer].
Nishimura K; Nakai Y; Shimizu K; Tokizane T; Arai Y; Inoue H; Takaha N; Nonomura N; Okuyama A; Kamoi K; Ukimura O; Miki T; Koide T; Ichikawa Y; Nishimura K; Sugao H; Yamaguchi S; Takatera H; Uchida K; Miura H
Hinyokika Kiyo; 2002 Nov; 48(11):713-8. PubMed ID: 12512147
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
[TBL] [Abstract][Full Text] [Related]
20. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy.
Khil MS; Kim JH; Bricker LJ; Cerny JC
Cancer J Sci Am; 1997; 3(5):289-96. PubMed ID: 9327153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]